Literature DB >> 16292485

Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years.

Dorothee Koch, Wolfgang Wick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16292485     DOI: 10.1007/s11060-005-9019-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  5 in total

1.  One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.

Authors:  W Wick; J P Steinbach; W M Küker; J Dichgans; M Bamberg; M Weller
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

2.  How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.

Authors:  Wolfgang Wick; Michael Weller
Journal:  J Clin Oncol       Date:  2005-06-20       Impact factor: 44.544

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

5.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

Authors:  W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

  5 in total
  1 in total

1.  Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.

Authors:  Florian Stockhammer; Martin Misch; Arend Koch; Marcus Czabanka; Michail Plotkin; Cristiane Blechschmidt; Jochen Tuettenberg; Peter Vajkoczy
Journal:  J Neurooncol       Date:  2010-05-06       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.